Figure 4
From: Evidence for a role of NTS2 receptors in the modulation of tonic pain sensitivity
Antinociceptive response to NT69L in the formalin tonic pain model. Intrathecal administration of the non-discriminative NTS1-NTS2 agonist, NT69L significantly blocks phase 2 lifting (a) but also abolishes the other specific behavioral (b) observed during the inflammatory phase. Values represent means ± SEM. ** P < 0.01 and *** P < 0.001 when compared with the vehicle-treated group (ANOVA followed by Dunnett's multiple comparison test).